<p>Carasent AB (publ) reported its earnings for the fourth quarter (Q4) and full year (FY) 2025. For Q4 2025, net sales reached SEK 93.6 million, reflecting a 19% increase. Organic growth accounted for 16%, while net acquisitions and divestments contributed SEK 3.0 million, or 4 percentage points of growth. EBITDA for the quarter was SEK 23.8 million, resulting in an EBITDA margin of 25%. Adjusted EBITDA margin also stood at 25%. Operating result (EBIT) for the period was SEK 7.8 million. Profit after tax amounted to SEK 29.1 million, with earnings per share, before and after dilution, at SEK 0.42. Cash flow from operating activities totaled SEK 20.6 million. For the full year 2025, revenues amounted to SEK 344 million, EBITDA reached SEK 73 million, and EBITDAC was SEK 34 million. The company reported that these results were in line with its updated financial targets announced in July 2025. During the period, Carasent AB (publ) implemented a long-term incentive program for senior executives and key employees, issuing up to 500,000 warrants. At the end of Q4, the group employed 196 individuals, with 115 in research and development, 18 in sales and marketing, and 15 in group management. No significant events were reported after the end of the period. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carasent AB (publ) published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

Reuters

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

VG Health

iShares Biotechnology ETF

iShares Global Healthcare

SPDR S&P Biotech

iShares US Pharma

Health Care Select Sector SPDR

VanEck Biotech ETF

Ark Genomic Revolution ETF

Cara Therap

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Carasent Q4 EBITDA rises to SEK 23.8 million, up 3.7 times year-on-year